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Abstract
We report here that polyethylene glycol (PEG) linked to near infrared dyes conjugated to chimeric mouse-human anti-
carcinoembryonic antigen (CEA) antibody greatly improves imaging of liver metastases in a nude mouse model of colon-
cancer experimental metastases. PEGylated and non-PEGylated DyLight 650 and 750 dyes were conjugated to the chimeric
anti-CEA antibody. The dyes were initially injected intravenously into nude mice without tumors. Tissue biodistribution was
determined by tissue sonication and analyzing tissue dye concentration profiles over time. PEGylated dyes had significantly
lower accumulation in the liver (p = 0.03 for the 650 dyes; p = 0.002 for the 750 dyes) compared to non-PEGylated dyes. In an
experimental liver metastasis model of HT-29 colon cancer, PEGylated dyes conjugated to the anti-CEA antibody showed
good labeling of metastatic tumors with high contrast between normal and malignant tissue which was not possible with
the non-PEGylated dyes since there was so much non-specific accumulation in the liver. PEGylation of the DyLight 650 and
750 NIR dyes significantly altered tissue biodistribution, allowing brighter tissue labeling, decreased accumulation in normal
organs, particularly the liver. This enabled high fidelity and high contrast imaging of liver metastases.
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Introduction
The use of fluorescence imaging has become widespread in
mouse models of cancer and has begun to make an impact in the
clinical care of patients [1,2]. Fluorescently-tagged tissues of
interest allow for easy detection and demarcation from other
structures in both living and fixed tissues. In living tissue this allows
for differential imaging of cells or molecules without disrupting
other biological processes and also allows for real-time imaging
[1].
Fluorescence-guided surgery (FGS), using a variety of tech-
niques, has been evaluated in mouse models and humans and has
been shown to facilitate evaluation of critical structures and
improved resection of tumors [3–11]. In an effort to bring FGS to
the clinic, we have developed FGS in orthotopic mouse models of
pancreatic and colon cancer by labeling the tumor with tumor-
specific monoclonal mouse antibodies conjugated to Alexa Fluor
488, a green fluorophore [12,13] as well as labeling with a tumor-
specific adenovirus [11]. In subsequent studies, minimally invasive
fluorescence laparoscopy was used to successfully image orthotopic
pancreatic tumors in mice labeled with fluorophore conjugated
monoclonal mouse antibodies to CEA [14,15].
The chimeric anti-CEA antibody used in the present study
comprises a murine variable domain and a human constant
domain. As non-human proteins, mouse antibodies tend to evoke
an immune reaction if administered to humans. The chimerization
process involves engineering the replacement of segments of the
antibody molecule that distinguish it from a human antibody. The
chimeric anti-CEA antibody has a human constant domain,
thereby eliminating most of the potentially immunogenic portions
of the antibody without altering its specificity for the intended
target.
In recent studies in an orthotopic model of pancreatic cancer,
we conjugated the chimeric anti-CEA antibody to variety of visible
and NIR dyes to evaluate their ability to penetrate skin,
peritoneum, and liver. We observed uptake of antibody-dye
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conjugate in the liver which hampered the ability to image liver
metastases [16].
Polyethylene glycol (PEG) conjugation has been employed to
decrease immunogenicity and improve pharmacokinetics of many
drugs, peptides and compounds [17]. PEGylation is currently
considered one of the most effective methods of prolonging the
residence time of biologically active proteins in the bloodstream
[18–20]. We hypothesized that by using a PEGylated NIR dye
conjugated to a chimeric anti-CEA antibody, hepatic accumula-
tion of the dye-antibody conjugate could be prevented resulting in
a high signal to background ratio (SBR) and thus facilitating the
imaging of hepatic metastases.
Materials and Methods
Cell Culture
The human colon cancer cell line HT-29 was obtained from the
American Type Culture Collection (Manassas, VA) and was
maintained in RPMI 1640 medium supplemented with 10% fetal
bovine serum (FBS) and 2 mM glutamine from Gibco-BRL, Life
Technologies, Inc. (Grand Island, NY). Cells were cultured at
37uC in a 5% CO2 incubator. The HT-29 cells were stably
transfected with red fluorescent protein (RFP) or green fluorescent
protein (GFP) as previously described [1,10,21].
Antibody-Dye Conjugation
Chimeric anti-CEA antibody (Aragen Biosciences, Morgan Hill,
CA) was conjugated to PEGylated and non-PEGylated DyLight
dyes (Thermo Fisher Scientific, Rockford, IL) per manufacturer
specifications, ensuring a minimum dye:protein ratio of at least 4:1
(Figure 1). For each mole of antibody, there were 4 moles of dye.
Protein:dye concentrations and ratios were confirmed using a
NanoDrop Spectrophotometer (Thermo Fisher Scientific, Rock-
ford, IL).
Animal Care
Athymic nu/nu nude mice (AntiCancer, Inc., San Diego, CA)
between 4 and 6 weeks of age were maintained in a barrier facility
on high efficiency particulate air (HEPA)-filtered racks. The
animals were fed with an autoclaved laboratory rodent diet
(Teckland LM-485; Western Research Products, Orange, CA). All
surgical procedures and imaging were performed with the animals
anesthetized by intramuscular injection of 0.02 ml of a solution of
50% ketamine, 38% xylazine and 12% acepromazine maleate.
When inhalational anesthesia was required, 2% isoflurane was
delivered via a vaporizer. All animal studies were conducted with
an AntiCancer Institutional Animal Care and Use Committee
(IACUC)-protocol specifically approved for this study and in
accordance with the principals and procedures outlined in the
National Institute of Health Guide for the Care and Use of
Animals under Assurance Number A3873-1. Animals received
Buprenorphine 0.10 mg/kg ip immediately prior to surgery and
once a day over the next 3 days to ameliorate suffering. CO2
inhalation was used for euthanasia. To ensure death following
CO2 asphyxiation, cervical dislocation was performed.
Tissue Biodistribution
2.5 nmol (94 mg) of dye conjugated to anti-CEA antibody in
100 ml PBS was injected into the tail vein of 60 nude mice. Three
mice were then subsequently sacrificed at various time points: 5
minutes, 30 minutes, 1 hour, 3 hour, 6 hour and 24 hours. An
incision was made from the sternum to the lower abdomen and the
whole mouse opened to ensure complete visualization of the
viscera. Imaging was performed using the OV-100 Small Animal
Imaging System (Olympus, Tokyo, Japan).
From the same group of mice 5 mg of liver tissue was obtained.
In each case 200 ml PBS was added to the tissue, which was
subsequently homogenized by sonication with a probe Branson
Figure 1. Schematic comparison of anti-CEA chimeric antibodies with PEGylated and non-PEGylated NIR dyes. Four mPEG200 chains
are covalently linked to each dye molecule, 4 of which are covalently linked to the chimeric anti-CEA antibody by amide bonds. The mPEG chains alter
tissue biodistribution, allowing brighter liver metastases labeling and decreased accumulation in normal organs, particularly the liver.
doi:10.1371/journal.pone.0097965.g001
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450 sonifier (Branson Ultrasonics Corp., Danbury, CT) at 20 KHz
until complete liquefaction.
The homogenized tissue was subsequently centrifuged at
5000 rpm for 3 minutes and the supernatant with dye collected.
100 ml of each sample was placed in a 96-well plate and diluted to
200 ml. The sample was placed in the plate reader and the
absorbance from each sample collected. Using standard curves,
the sample concentration of dye was determined, allowing for
determination of dye concentration in the tissue in nmol/mg.
Tissue concentrations of each dye were plotted over time.
Liver metastasis formation and labeling
HT-29-RFP colon cancer cells (16106) were injected into the
spleen of nude mice as previously described [22]. The cells
trafficked in the liver parenchyma and formed liver metastases
over a period of 4 weeks. After ensuring the presence of liver
metastases by non-invasive whole body imaging, the mice were
injected with anti-CEA antibody conjugated to either DyLight
650-PEG or DyLight 750-PEG, or conjugated to the non-
PEGylated equivalent dyes. Two mice were used per group.
Twenty-four hours later, the mice were sacrificed and a ventral
vertical incision from the sternum to the lower abdomen made to
facilitate complete visceral exposure for imaging.
To further determine the specificity of the conjugated antibod-
ies, mice with HT-29-GFP liver metastases as described above
were treated as follows: Mouse 1: DyLight 750 PEG Anti-CEA
antibody conjugate, Mouse 2: Unconjugated DyLight 750 PEG,
Mouse 3: DyLight 650 PEG Anti-CEA antibody conjugate, Mouse
4: Unconjugated DyLight 650 PEG. After 24 hours, the mice were
sacrificed and a ventral vertical incision from the sternum to the
lower abdomen was made to facilitate complete visceral exposure
for whole body imaging. The mice were then imaged using the
OV-100 Small Animal Imaging System (Olympus, Tokyo, Japan).
In each instance images were taken with the liver in anatomical
position and with the liver lifted up to expose the inferior surface of
the liver.
Animal Imaging
Mice were imaged using the Olympus OV100 Small Animal
Imaging System (Olympus Corp. Tokyo, Japan), containing an
MT-20 light source (Olympus Biosystems Planegg, Germany) and
DP70 CCD camera (Olympus Corp. Tokyo, Japan). The OV100
Figure 2. Whole body time sequence images of both PEGylated and non-PEGylated dye-anti-CEA antibody conjugates to evaluate
total body biodistribution. After the mice are sacrificed at the indicated time-points, they were opened up from sternum to pubis to completely
expose the viscera. In 2a, DyLight 650 anti-CEA antibody conjugate is evaluated, with images taken at different time-points. The top row is the
PEGylated dye anti-CEA antibody conjugate, while the bottom row is the non-PEGylated anti-CEA antibody conjugate. With the PEGylated anti-CEA
antibody conjugate, there is minimal to no accumulation of dye in the viscera, while in the non-PEGylated anti-CEA antibody conjugate, there is
accumulation of dye in the reticulo-endothelial system organs such as the liver and lung. Arrows in the bottom row point to lymph nodes that
retained and were labeled by the dye. In 2b, DyLight 750 is evaluated, with images taken at different time-points. The top row is the PEGylated dye
anti-CEA antibody conjugate, while the bottom row is the non-PEGylated anti-CEA antibody conguate. With the PEGylated anti-CEA antibody
conjugate, there was minimal to no accumulation of dye in the viscera, while in the non-PEGylated anti-CEA antibody conjugate there was
accumulation of dye in the liver and lung. Arrows in the bottom row point to lymph nodes that retained and were labeled by the dye.
doi:10.1371/journal.pone.0097965.g002
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was used due to its unique ability to accomplish high fidelity
fluorescence imaging with variable magnification capabilities that
allow for imaging of not only the whole animal but also at the
subcellular level. The instrument incorporates a unique combina-
tion of variable magnification, high numerical aperture, and long
working distance. Four individually optimized objective lenses,
parcentered and parfocal provide a 105 fold magnification range
for seamless imaging of the entire body down to the subcellular
level without disturbing the animal [23]. In addition, openings on
the machine allow for delivery of inhalational anesthesia to the
animal without allowing entry of outside light. This allows for
capturing high quality in-vivo images with minimal morbidity to
the animal by avoiding anesthetic injections. All images were
analyzed using Image-J (National Institute of Health Bethesda,
MD) and were processed with the use of Photoshop elements-11
(Adobe Systems Inc. San Jose, CA).
Frozen Section Preparation
Mice were injected with 2.5 mmol (94 mg) anti-CEA antibody
conjugated to PEGylated DyLight 650. 48 hours later, the
antibody-labeled HT-29 RFP liver metastases were harvested.
The tumor was placed in OCT compound and subsequently
dipped into liquid nitrogen. Once the tumor was frozen, it was
placed on a microtome and sliced into 5 mm sections and placed
on a glass slide and immediately dipped in 95% ethanol for
fixation. Alternate slides were stained with H&E for fluorescence
and brightfield imaging. Fluorescence and confocal imaging were
done with the FV1000 Confocal Laser Scanning Biological
Microscope (Olympus Corp. Tokyo, Japan) [24].
Statistical Analysis
All statistical analysis was done using SPSS software version 21
(IBM, Armonk, NY). For the pairwise comparisons within the
Figure 3. Liver tissue concentrations of the dye anti-CEA antibody conjugates over time. The liver was assayed to demonstrate tissue
accumulation of the non-PEGylated and PEGylated 650 and 750 dyes that were conjugated to chimeric anti-CEA antibody. The non-PEGylated 650
(panel A) and 750 dye antibody conjugates (panel B) accumulated to significantly higher levels in the liver compared to their respective PEGylated
dye antibody conjugates.
doi:10.1371/journal.pone.0097965.g003
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650 nm and 750 nm groups, quantitative variables were com-
pared using the paired samples student t-test and confirmed with
the Wilcoxon rank-sum test. A p-value ,0.05 was considered
significant. 95% confidence intervals obtained on analysis of the
data were configured into all the error bars of the appropriate
figures and graphs.
Results
Tissue biodistribution of PEGylated and non-PEGylated
dyes conjugated to anti-CEA antibody
PEGylation significantly altered the biodistribution and elimi-
nation patterns of both the dyes. With PEGylation, little to no
accumulation of dye conjugated to the antibody was noted in
normal hepatic tissue (Figures 2 a&b). Dye was visualized in the
kidneys, ureters and bladder indicating some component of renal
elimination for both PEGylated and non-PEGylated dyes. Both
PEGylated 650 and 750 dyes had significantly lower liver
concentrations compared to the non-PEGylated counterparts in
non-tumor-bearing mice with p= 0.03 for the 650 group and
p= 0.002 for the 750 group (Figure 2 a&b and Figure 3).
High-resolution labeling of liver metastases by PEGylated
dyes conjugated to anti-CEA antibody
The non-PEGylated dyes accumulated extensively in the liver,
which precluded imaging of metastatic disease to the liver.
Therefore, we imaged mice bearing HT-29 colon cancer liver
metastases using anti-CEA antibody labeled with 650-PEG
(Figure 4a) or 750-PEG (Figure 4b). The liver metastases were
readily visualized in the liver with minimal background fluores-
cence of normal liver (Figure 4 a & b). Furthermore, when labeled
by the PEGylated dye-mAb complex, more of the metastatic
tumor was visible when compared to the genetic RFP signal of the
cancer cells (Figure 4 a & b).
Comparison of labeling with PEGylated dyes conjugated
to anti-CEA and histology to distinguish liver metastases
The chimeric anti-CEA antibody conjugated with the PEGy-
lated dyes labeled the liver metastases much more clearly than
normal hepatic parenchyma and distinguished the metastases
Figure 4. Liver metastasis models. In 4a, the PEGylated 650 anti-CEA antibody conjugate was injected into the mouse 24 hours prior to imaging.
While the liver metastases are partially visible on bright field imaging, the anti-CEA antibody conjugated to PEGylated dye accurately and selectively
labeled the tumors showing the true extent of disease. The RFP signal visualizes less of the tumor in comparison to the 650 nm signal from the anti-
CEA chimeric antibody conjugated to PEGylated dyes, as demonstrated by the arrowheads. Any deep tumor or tumor overlain by liver tissue was not
visualized with the RFP signal due to the poor penetration and hemoglobin quenching of the 550 nm signal. Upper and lower panels show same
mouse with liver lifted up in lower panel in order to show additional view of liver metastases. In 4b, the PEGylated 750 anti-CEA antibody conjugate
was injected into the mouse 24 hours prior to imaging. The liver metastases in this case are barely visible on bright field imaging. The PEGylated anti-
CEA antibody conjugate however, brightly labels the metastases showing the true extent of disease. The RFP signal did not demonstrate the true
extent of disease due to low tissue penetration and hemoglobin quenching when compared to the 750 nm signal. Upper and lower panels show
same mouse with liver lifted up in lower panel in order to show additional view of liver metastases.
doi:10.1371/journal.pone.0097965.g004
Figure 5. Demonstration of metastatic colon cancer cells
adjacent to hepatic tissue. H&E, confocal and fluorescence images
of adjacent tissue samples are shown (Confocal and fluorescence
images from same slide). The tumor margin was much better
delineated when employing fluorescence microscopy.
doi:10.1371/journal.pone.0097965.g005
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better than conventional H&E staining (Figure 5). The antibody-
labeling was specific for the HT-29-GFP liver metastases since the
corresponding free dyes did not show any tumor labeling
(Figure 6).
Discussion
In the present study, we demonstrated that PEG conjugation of
NIR dyes conjugated to a chimeric anti-CEA antibody enhances
imaging of liver metastases in nude-mouse models. With 4 mPEG
chains conjugated to each dye molecule and 4–6 dye molecules
conjugated to each mAb, this would have given each conjugated
antibody molecule a minimum coverage of at least 16 mPEG
chains. The change in biodistribution due to PEGylation of dyes
conjugated to anti-CEA antibody results in less non-specific
distribution of dye, allowing for a higher-signal-to-background
ratio (SBR), especially in the reticuloendothelial organs compared
to anti-CEA antibody conjugated to non-PEGylated dyes.
Regarding specificity, we have recently shown that the chimeric
fluorophore-conjugated CEA antibody used in the present study
demonstrated more effective labeling of human CEA-expressing
cancer in tissue arrays and in patient-derived orthotopic xenograft
(PDOX) nude models of human patient colon cancer. In this
study, there was minimal labeling in the normal liver and lung
tissue but significantly greater fluorescence signal intensity in
labeled CEA-expressing colon, lung and pancreas tumor tissues.
There was no labeling of CEA-negative tumors of the prostate,
skin, ovary, uterus, brain, small intestine, kidney, stomach, and
liver. There was also very minimal labeling of any tissue, normal
or tumor, with the negative control IgG antibody [25].
In another experiment to demonstrate specificity of the anti-
CEA antibody conjugated to PEGylated dyes, the free PEGylated
dyes were compared to their anti-CEA-conjugated counterparts.
There was a striking difference in that only the antibody-
conjugated dyes labeled the liver metastases. The free PEGylated
dyes demonstrated no labeling of the metastases. Thus the
conjugated antibody with PEGylated dyes is highly specific to
label the metastases.
The RFP label of the tumors was not as clearly discernible with
less of the tumor being visualized when compared to both DyLight
650-PEG and 750-PEG labeling. Any deep tumors or tumors
covered by liver tissue were unable to be visualized with the RFP
signal.
Only two NIR dyes are currently FDA approved, ICG and
methylene blue (MB). ICG fluoresces at <800 nm and MB, which
when diluted to levels almost undetectable to the human eye
fluoresces at <700 nm, a phenomenon known as ‘unquenching’
[26–28]. ICG permits imaging of intrahepatic and biliary
structures, while MB permits imaging of both bile ducts and
ureters [29,30]. ICG has been most studied in liver imaging, but is
non-specific [31,32], contaminates the GI tract due to biliary
secretion and is not very bright [33], and is unable to be covalently
conjugated to targeting ligands [34].
Figure 6. Specificity of anti-CEA antibody conjugated dyes as compared to free dyes. In all images from A to D, the top panel of images is
taken with the liver in anatomical position and the bottom panel is taken with the liver flipped upward to enable visualization of the undersurface.
Image A is taken 24 hours after injection of the 750 PEG-anti-CEA antibody conjugate. Imaging at 750 nm clearly delineates all the HT-29-GFP liver
metastases which are not completely visible on imaging with brightfield or GFP imaging (see arrows). Image B is taken 24 hours after injection of the
750 PEG dye only. No visible tumor labeling is noted, with little to no visualization of the dye throughout the animal, despite the GFP signal of the
tumor being clearly detected. Image C is taken 24 hours after injection of the 650 PEG-anti-CEA antibody conjugate. There is very precise and clear
labeling of tumor that is detected at 650 nm, which correlates well with the GFP signal. With the liver in the anatomical position, the gallbladder is
also noted emerging from the underside of the liver. On the underside of the liver, a tumor is detected that is not visible on either GFP or brightfield
imaging (see arrows). Image D is taken 24 hours after injection of the 650PEG free dye. There is non-specific distribution of the dye noted at 650 nm,
with no selectivity for the tumor despite there being a robust GFP signal.
doi:10.1371/journal.pone.0097965.g006
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The present study demonstrated that PEGylated NIR dyes
conjugated to a chimeric tumor-specific antibody show promise in
use for imaging of liver metastases with their high SBR within the
liver, the ability to bind to a target ligand and lack of GI
contamination due to absence of biliary excretion. The dyes show
promise in imaging of metastatic or intrinsic hepatobiliary
malignancies and should be useful for imaging of tumors in any
tissue of interest as the dyes minimally accumulate non-specifically
and they are very bright with high SBR and should have great
potential for fluorescence-guided surgery.
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